PEP (post-exposure prophylaxis) prevents HIV from establishing a permanent infection in your body, and if it succeeds, you have no virus to pass on to anyone else. In animal studies, PEP reduced the chance of seroconversion by roughly 89%, and when taken correctly and on time, it works for the overwhelming majority of people. But PEP is not a guarantee, and during the 28 days you are taking the medication, your HIV status is genuinely uncertain. That uncertainty matters for anyone you have sexual contact with during and shortly after the course.
How PEP Stops the Virus From Taking Hold
PEP uses the same class of antiretroviral drugs that treat established HIV infections, but the goal is different. Instead of managing a lifelong infection, PEP intercepts the virus during the narrow window before it can integrate into your immune cells and start replicating permanently. The drugs target different stages of the viral life cycle inside the body, blocking the virus from copying itself and spreading from cell to cell. If the medications keep viral replication suppressed long enough, the small amount of virus from the initial exposure is eliminated before a permanent reservoir forms.
This is why timing matters so much. The CDC’s 2025 guidelines emphasize that the shorter the gap between exposure and starting PEP, the better it works. The 72-hour initiation window was originally established through primate studies showing that efficacy drops steadily the longer you wait after exposure. Starting within hours is ideal; starting at 71 hours is far less reliable than starting at 4 hours. Once you begin the 28-day course, the drugs need to be taken consistently every day to maintain high enough drug levels to keep the virus from gaining a foothold.
Why Your HIV Status Is Uncertain While on PEP
Here is the uncomfortable reality that most people on PEP wrestle with: for the entire duration of the 28-day course and for several weeks afterward, you do not definitively know whether the medication worked. HIV tests detect either antibodies your immune system produces in response to the virus or the virus itself, and PEP can delay or suppress both of those signals. A negative test during the PEP course does not mean you are in the clear. It might just mean the drugs are keeping viral levels too low to detect.
This is where the question of infecting someone else becomes genuinely tricky. If PEP is working as intended, the virus never gains a foothold and you have nothing to transmit. But if PEP is failing, the virus may be replicating at low levels in your body, potentially present in blood, semen, or vaginal fluids, yet still too low for standard tests to pick up. You would not know you were infected, and depending on viral levels in genital fluids, transmission to a partner could theoretically occur.
Research on early HIV infection and antiretroviral therapy gives some indirect insight into what happens in this scenario. A study tracking viral load in plasma and semen during primary HIV infection found that among people who started antiretroviral therapy immediately at diagnosis, viral load in both plasma and semen dropped below 1,000 copies per milliliter. Among those who did not start treatment, semen viral load stayed above 1,000 copies per milliliter in the vast majority of samples collected during the first ten weeks, a level consistent with transmissibility. The takeaway: antiretroviral drugs do suppress viral load in genital fluids even in early infection, which would reduce transmission risk. But “reduce” is not “eliminate,” and during PEP you have no way to monitor your viral load in real time.
When PEP Fails
PEP does not work every time. In primate studies, the odds of seroconversion were about 89% lower with PEP compared to no treatment, which is a dramatic reduction but not zero. Several factors influence whether PEP succeeds in humans:
- Timing: Starting PEP later in the 72-hour window gives the virus more time to establish itself before the drugs can intervene.
- Adherence: Missing doses or stopping the course early lowers drug levels enough for the virus to replicate past the point of no return.
- Drug resistance: If the virus you were exposed to carries resistance mutations to the PEP medications, the drugs may not suppress replication effectively. Early case reports of zidovudine PEP failures flagged reduced drug sensitivity in the transmitted strains as a possible explanation.
- Exposure severity: A high-dose exposure, such as a needlestick with a large volume of blood from someone with a high viral load, challenges PEP more than a lower-risk exposure.
If PEP fails, you will go through acute HIV infection while still taking the medications. The antiretrovirals may partially suppress viral replication, which can mask symptoms and delay the point at which standard tests turn positive. During this period, you could have virus in your blood and genital fluids at levels that allow transmission, even though you feel fine and your tests have not yet turned positive. This is one of the strongest arguments for using condoms and avoiding needle-sharing throughout the PEP course and until follow-up testing confirms your status.
The Hidden Risk of Already Being Infected
One scenario that catches people off guard is starting PEP when you are actually already HIV-positive from a previous exposure you did not know about. If you were infected days or weeks before the exposure that prompted PEP, the virus has already established a permanent reservoir in your body. PEP will not cure that infection. Instead, you will be taking a two- or three-drug regimen that functions as incomplete treatment rather than prevention.
A scoping review examining challenges of HIV diagnosis in the context of PEP and PrEP highlighted this problem directly. Missed acute HIV infection prevents people from accessing early treatment, increases the likelihood of onward transmission, and can allow inappropriate continuation of prophylaxis, which risks the development of drug resistance. The drugs in PEP overlap with standard treatment regimens, and taking an incomplete regimen when you already have an established infection gives the virus an opportunity to develop mutations that make those drugs less effective in the future.
This is why clinicians test you for HIV before prescribing PEP and again at follow-up. If you had a separate exposure in the weeks before the one that brought you to the clinic, your baseline test might still be negative because you are in the “window period” of that earlier infection. Rapid antigen/antibody tests can miss very early infections. The practical implication: if you have had multiple recent exposures, make sure your provider knows, so they can interpret your test results with that context in mind.
How Adherence Shapes Your Risk and Everyone Else’s
Sticking with the full 28-day PEP course is one of the most important factors in whether it works, and adherence is a bigger challenge than most people expect. A meta-analysis of cohort studies found that side effects occurred in about 60% of PEP users, and roughly a third of people discontinued PEP because of adverse drug reactions. The most common complaints are nausea, fatigue, and diarrhea, which can be enough to make someone stop taking pills, especially when the exposure risk felt low to begin with.
Newer drug combinations have improved this picture. A study of the single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide found that over 90% of participants completed the full course. Side effects like nausea or vomiting occurred in about 15% of people, fatigue in about 10%, and diarrhea in about 8%, all of which were less common than with older PEP regimens. Only one participant stopped the regimen because of side effects, and none of the participants became HIV-positive. That completion rate is a significant improvement over older protocols, where a third of people dropping out left a meaningful gap in protection.
Every missed dose matters. Antiretroviral drugs need to stay above a certain concentration in your blood and tissues to keep the virus from replicating. If you skip pills or take them irregularly, drug levels can dip below that threshold, giving the virus a window to establish itself. Once a permanent viral reservoir forms, PEP has failed and you have an infection that requires lifelong treatment. During any period of incomplete drug coverage, the virus could also be replicating at levels that allow transmission to others.
Practical Precautions During the PEP Course
Because you cannot know your HIV status with certainty while on PEP, the safest approach is to act as if transmission is possible. That means using condoms for all sexual contact and not sharing needles or drug-injection equipment for the entire 28 days plus the follow-up testing period. This is not an academic recommendation; it is the practical reality of dealing with a period of genuine uncertainty.
The good news is that even in a worst-case scenario where PEP is failing and you are developing an infection, the antiretroviral drugs you are taking would be actively suppressing viral replication, lowering the amount of virus in your blood and genital secretions. Research on per-act HIV transmission risk found that sexual exposure risks were reduced by over 99% with the combined use of condoms and antiretroviral treatment of the infected partner. While that study looked at treatment of known HIV-positive individuals rather than PEP specifically, the principle holds: antiretroviral drugs in your system significantly reduce the viral load available for transmission, and condoms add a powerful additional layer of protection.
Some people worry about transmission risk from kissing, sharing utensils, or casual contact during PEP. These are not routes of HIV transmission regardless of whether you are on PEP. HIV requires specific body fluids, primarily blood, semen, vaginal fluids, or breast milk, and a route of entry such as a mucous membrane, damaged tissue, or direct injection. Casual contact poses no risk whether or not you are taking PEP.
Testing After PEP and When You Know for Sure
The only way to confirm that PEP worked is through follow-up HIV testing after the course is finished. Guidelines generally recommend testing at defined intervals after completing PEP, because the drugs can delay seroconversion. A negative test at the end of the 28-day course is encouraging but may be too early to be conclusive. Testing at around four to six weeks after the exposure, and again at three months, gives a much more reliable picture. Fourth-generation antigen/antibody tests can detect infection earlier than older antibody-only tests, but even these have a window period.
Until you have a confirmed negative test at the appropriate interval after finishing PEP, the cautious assumption is that your status remains unknown. Many people find this waiting period stressful, which is understandable. The overwhelming likelihood, especially if you started PEP promptly and took every dose, is that the medication worked. But “overwhelming likelihood” is not certainty, and your sexual partners deserve the same honesty about that uncertainty that you would want from them.
Transitioning From PEP to PrEP
If you sought PEP because of a sexual exposure, your provider may raise the question of whether PrEP (pre-exposure prophylaxis) makes sense for you going forward. PrEP is a daily or event-based medication taken before potential exposure, and it is far more effective as a long-term prevention strategy than relying on PEP after the fact. Some clinics have formalized this transition. An observational study of a nurse-led program offered patients an appointment to start PrEP at the point of PEP initiation, with a follow-up offer at two weeks and a PrEP clinic visit after about three weeks of PEP.
The logic behind starting PrEP soon after finishing PEP is straightforward: if your circumstances put you at ongoing risk, there should be no gap in protection. Finishing a 28-day PEP course and then having another unprotected exposure a week later puts you right back at square one, seeking emergency medication again. PrEP, taken consistently, reduces the risk of acquiring HIV from sexual contact by over 99% when adherence is high. If you find yourself needing PEP more than once, that pattern is a strong signal that PrEP would serve you better.
What About Breastfeeding and Other Special Situations
The question of transmission during PEP takes on a different dimension in the context of mother-to-child transmission. When an infant is given post-exposure prophylaxis to prevent HIV acquisition through breastfeeding, the concern is not about the infant infecting someone else but about whether the drugs adequately protect the baby from ongoing exposure through breast milk. A randomized trial comparing PEP regimens in infants of untreated mothers found that breastfeeding was independently associated with an increased odds of infection following birth, alongside higher maternal viral load and lower maternal CD4 cell counts.
The cumulative nature of breastfeeding exposure makes this situation fundamentally different from a single sexual or needlestick event. In adult PEP, you are trying to block a one-time exposure. In breastfeeding, the exposure is continuous for months, and the infant’s PEP needs to account for repeated viral challenges. A review of transmission risk in newborns noted that per-month risk during breastfeeding is very low when the mother is on antiretroviral therapy, but cautioned that the cumulative risk over the entire breastfeeding period can be significant. Extended infant prophylaxis in these settings is an area where data on efficacy remains thin, and the potential toxicity of prolonged drug exposure in infants adds another layer of concern.
Drug Resistance and What It Means for Future Treatment
If PEP fails and you do become HIV-positive, the drugs you were taking during the PEP course may have given the virus a chance to develop resistance mutations, particularly if adherence was inconsistent. Taking antiretroviral drugs at subtherapeutic levels, whether because of missed doses or because the regimen was not potent enough against the specific strain, creates selective pressure that favors resistant viral variants. Early case reports of PEP failures with zidovudine identified reduced drug sensitivity in transmitted strains as one possible explanation.
Modern PEP regimens use more potent drug combinations with higher barriers to resistance than the single-drug zidovudine protocols of the 1990s. The current standard involves two or three drugs from different classes, which makes it much harder for the virus to develop resistance to all of them simultaneously. Still, incomplete courses remain the biggest modifiable risk factor for resistance. If you cannot tolerate a particular regimen, contacting your provider to switch medications is far better than simply stopping. A different combination may have fewer side effects while still maintaining protection. And if PEP does fail, knowing exactly which drugs you took and for how long helps your treatment team choose an effective long-term regimen that avoids the drugs the virus may have already learned to evade.